Philip H. Howard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Philip H. Howard has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Derek C. G. Muir
School of Environmental Sciences, University of Guelph, Guelph, Ontario N1G 2W1, Canada
2 shared publications Bill Meylan
SRC, Inc., 7502 Round Pond Road, North Syracuse, New York 13212, USA
1 shared publicationDallas Aronson
SRC, Inc., 7502 Round Pond Road, North Syracuse, New York 13212, USA
1 shared publicationJohn Weeks
S.C. Johnson & Son, Inc., Racine, Wisconsin, USA
1 shared publicationPatrick D Guiney
S.C. Johnson & Son, Inc., Racine, Wisconsin, USA
1 shared publication
Latest Publications
- 17 April 2013
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 47 (10) , 5259-5266
Identifying New Persistent and Bioaccumulative Organics Among Chemicals in Commerce. III: Byproducts, Impurities, and Transformation Products
The goal of this series of studies was to identify commercial chemicals that might be persistent and bioaccumulative (PB) and that were not being considered in current wastewater and aquatic environmental measurement programs. In this study, we focus on chemicals that are not on commercial chemical lists such as U.S. EPA’s Inventory Update Rule but may be found as byproducts or impurities in commercial chemicals or are likely transformation products from commercial chemical use. We evaluated the 610 chemicals from our earlier publication as well as high production volume chemicals and identified 320 chemicals (39 byproducts and impurities, and 281 transformation products) that could be potential PB chemicals. Four examples are discussed in detail; these chemicals had a fair amount of information on the commercial synthesis and byproducts and impurities that might be found in the commercial product. Unfortunately for many of the 610 chemicals, as well as the transformation products, little or no information was available. Use of computer-aided software to predict the transformation pathways in combination with the biodegradation rules of thumb and some basic organic chemistry has allowed 281 potential PB transformation products to be suggested for some of the 610 commercial chemicals; more PB transformation products were not selected since microbial degradation often results in less persistent and less bioaccumulative metabolites.
- 17 April 2013
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 47 (10) , 5259-5266
Identifying New Persistent and Bioaccumulative Organics Among Chemicals in Commerce. III: Byproducts, Impurities, and Transformation Products
The goal of this series of studies was to identify commercial chemicals that might be persistent and bioaccumulative (PB) and that were not being considered in current wastewater and aquatic environmental measurement programs. In this study, we focus on chemicals that are not on commercial chemical lists such as U.S. EPA’s Inventory Update Rule but may be found as byproducts or impurities in commercial chemicals or are likely transformation products from commercial chemical use. We evaluated the 610 chemicals from our earlier publication as well as high production volume chemicals and identified 320 chemicals (39 byproducts and impurities, and 281 transformation products) that could be potential PB chemicals. Four examples are discussed in detail; these chemicals had a fair amount of information on the commercial synthesis and byproducts and impurities that might be found in the commercial product. Unfortunately for many of the 610 chemicals, as well as the transformation products, little or no information was available. Use of computer-aided software to predict the transformation pathways in combination with the biodegradation rules of thumb and some basic organic chemistry has allowed 281 potential PB transformation products to be suggested for some of the 610 commercial chemicals; more PB transformation products were not selected since microbial degradation often results in less persistent and less bioaccumulative metabolites.
- 1 January 2012
- Published by Oxford University Press (OUP) in Integrated Environmental Assessment and Management
- Vol. 8 (1) , 135-166
Environmental release, environmental concentrations, and ecological risk of N,N-Diethyl-m-toluamide (DEET)
N,N‐Diethyl‐m‐toluamide's (DEET) commercial use as an insect repellent and other reported uses are reviewed. Evidence that DEET is reaching the environment mainly from consumer use of DEET‐containing insect repellent includes studies reporting higher concentrations of DEET in surface water and wastewater samples during the summer months, the presence of DEET in on‐site septic tank effluent at concentrations similar to that reported in wastewater treatment plant (WWTP) influent, and changes in WWTP effluent concentrations before and after the introduction of a DEET replacement in Germany. Its detected concentrations in influent and effluent of WWTP and surface water worldwide are reviewed and correlations between DEET usage and wastewater effluent concentrations are analyzed. The removability during wastewater treatment is also evaluated. A correlation between commercial DEET use in a metropolitan area and concentrations in WWTP effluents was assessed, and 2 different models were used to predict DEET concentrations in rivers and streams throughout the United States. Ecological toxicity data are reviewed for acute studies and for chronic values that are available for Daphnia magna and algae. The ecological risk of DEET usage is evaluated by examining the relationship of the expected dose/response to observed concentrations. Integr Environ Assess Manag 2012;8:135–166. © 2011 SETAC
- 1 January 2012
- Published by Oxford University Press (OUP) in Integrated Environmental Assessment and Management
- Vol. 8 (1) , 135-166
Environmental release, environmental concentrations, and ecological risk of N,N-Diethyl-m-toluamide (DEET)
N,N‐Diethyl‐m‐toluamide's (DEET) commercial use as an insect repellent and other reported uses are reviewed. Evidence that DEET is reaching the environment mainly from consumer use of DEET‐containing insect repellent includes studies reporting higher concentrations of DEET in surface water and wastewater samples during the summer months, the presence of DEET in on‐site septic tank effluent at concentrations similar to that reported in wastewater treatment plant (WWTP) influent, and changes in WWTP effluent concentrations before and after the introduction of a DEET replacement in Germany. Its detected concentrations in influent and effluent of WWTP and surface water worldwide are reviewed and correlations between DEET usage and wastewater effluent concentrations are analyzed. The removability during wastewater treatment is also evaluated. A correlation between commercial DEET use in a metropolitan area and concentrations in WWTP effluents was assessed, and 2 different models were used to predict DEET concentrations in rivers and streams throughout the United States. Ecological toxicity data are reviewed for acute studies and for chronic values that are available for Daphnia magna and algae. The ecological risk of DEET usage is evaluated by examining the relationship of the expected dose/response to observed concentrations. Integr Environ Assess Manag 2012;8:135–166. © 2011 SETAC
- 8 July 2011
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 45 (16) , 6938-6946
Identifying New Persistent and Bioaccumulative Organics Among Chemicals in Commerce II: Pharmaceuticals
The goal of this study was to identify commercial pharmaceuticals that might be persistent and bioaccumulative (P&B) and that were not being considered in current wastewater and aquatic environmental measurement programs. We developed a database of 3193 pharmaceuticals from two U.S. Food and Drug Administration (FDA) databases and some lists of top ranked or selling drugs. Of the 3193 pharmaceuticals, 275 pharmaceuticals have been found in the environment and 399 pharmaceuticals were, based upon production volumes, designated as high production volume (HPV) pharmaceuticals. All pharmaceuticals that had reported chemical structures were evaluated for potential bioaccumulation (B) or persistence (P) using quantitative structure property relationships (QSPR) or scientific judgment. Of the 275 drugs detected in the environment, 92 were rated as potentially bioaccumulative, 121 were rated as potentially persistent, and 99 were HPV pharmaceuticals. After removing the 275 pharmaceuticals previously detected in the environment, 58 HPV compounds were identified that were both P&B and 48 were identified as P only. Of the non-HPV compounds, 364 pharmaceuticals were identified that were P&B. This study has yielded some interesting and probable P&B pharmaceuticals that should be considered for further study.
- 8 July 2011
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 45 (16) , 6938-6946
Identifying New Persistent and Bioaccumulative Organics Among Chemicals in Commerce II: Pharmaceuticals
The goal of this study was to identify commercial pharmaceuticals that might be persistent and bioaccumulative (P&B) and that were not being considered in current wastewater and aquatic environmental measurement programs. We developed a database of 3193 pharmaceuticals from two U.S. Food and Drug Administration (FDA) databases and some lists of top ranked or selling drugs. Of the 3193 pharmaceuticals, 275 pharmaceuticals have been found in the environment and 399 pharmaceuticals were, based upon production volumes, designated as high production volume (HPV) pharmaceuticals. All pharmaceuticals that had reported chemical structures were evaluated for potential bioaccumulation (B) or persistence (P) using quantitative structure property relationships (QSPR) or scientific judgment. Of the 275 drugs detected in the environment, 92 were rated as potentially bioaccumulative, 121 were rated as potentially persistent, and 99 were HPV pharmaceuticals. After removing the 275 pharmaceuticals previously detected in the environment, 58 HPV compounds were identified that were both P&B and 48 were identified as P only. Of the non-HPV compounds, 364 pharmaceuticals were identified that were P&B. This study has yielded some interesting and probable P&B pharmaceuticals that should be considered for further study.